Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer

  • Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Cao, Jie (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Shi, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Xu, Xia (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Qian, Zhi-Ying (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
  • Published : 2014.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To highlight the potential factors that could predict the response rate of patients with metastatic colorectal cancer (mCRC) treated with pemetrexed combined chemotherapy after first- or second-line chemotherapy using the FOLFOX regimen. Materials and Methods: Between January 2007 and July 2014, 54 patients diagnosed and pathologically-confirmed with advanced colorectal cancer in Jiangsu Cancer Hospital and Research Institute, were enrolled. They received pemetrexed at a dose of $500mg/m^2$ by 10 minute infusion on day 1, repeated every 3 weeks. Doses were modified depending on nadir counts of blood cells. Combined chemotherapeutic agents included irinotecan, lobaplatin, carboplatin, oxaliplatin, gemcitabine, cis-platinum or bevacizumab. Multiple variables (age, sex, hemoglobin, platinum drugs combined, metastasis sites, LDH, ALP, CEA>40 ug/ml) reported earlier were selected. We used logistic regression analysis to evaluate relationships between these and tumor response. Results: On multivariable analysis, we found that age was significant in predicting the responsiveness to pemetrexed (p<0.05) combined with oxaliplatin. We did not find any other factors which were significantly associated with the response rate to chemotherapy with pemetrexed and irinotecan. Conclusions: By multivariate analysis, we found that age had significant impact on the responsiveness of pemetrexed when combined with oxaliplatin. Additional research based on genomic properties of host and tumors are needed to clarify markers for better selection of patients who could benefit from pemetrexed combined chemotherapy.

Keywords

References

  1. Calvert AH (2004). Biochemical pharmacology of Pemetrexed. Oncol (Williston Park), 18, 13-7.
  2. Cripps C, Burnell M, Jolivet J, et al (1999). Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol, 10, 1175-9. https://doi.org/10.1023/A:1008372529239
  3. C. Louvet (2004). Pemetrexed in advanced colorectal cancer. Oncology (Williston Park), 18, 56-62.
  4. Cao J, Huang XE, Liu J, Wu XY, Lu YY (2013). Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev, 14, 7171-7. https://doi.org/10.7314/APJCP.2013.14.12.7171
  5. Chen YS, Xu SX, Ding YB, et al (2013). Helicobacter pylori Infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac J Cancer Prev, 14, 7613-9. https://doi.org/10.7314/APJCP.2013.14.12.7613
  6. Chen YS, Xu SX, Ding YB, et al (2013). Colorectal cancer screening in high-risk populations: a survey of cognition among medical professionals in Jiangsu, China. Asian Pac J Cancer Prev, 14, 6487-91. https://doi.org/10.7314/APJCP.2013.14.11.6487
  7. de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
  8. Derwinger K, Kodeda K, Swartling T, et al (2011). A phase I/ II study of neoadjuvant chemotherapy with pemetrexed (Alimta) in rectal cancer. Eur J Surg Oncol, 37, 583-8 https://doi.org/10.1016/j.ejso.2011.04.003
  9. De Gramont A, Kindler HL (2002). Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol, 29, 42-49. https://doi.org/10.1053/sonc.2002.30763
  10. Douillard JY, Cunningham D, Roth AD, et al (2000).Irinotecan combined with fluorouracil compared with fluorouracil alone. As first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 25, 1041-7.
  11. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004). Synergistic cytotoxicity and pharmacogenetics of gemcitabine andpemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res, 10, 2936-43 https://doi.org/10.1158/1078-0432.CCR-03-0520
  12. Gong JP, Yang L, Huang XE, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery. Asian Pac J Cancer Prev, 15, 707-12. https://doi.org/10.7314/APJCP.2014.15.2.707
  13. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  14. Huang XE, Tian GY, Cao J, et al (2013). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. https://doi.org/10.7314/APJCP.2013.14.11.6663
  15. Hochster HS (2004). The role of pemetrexed in the treatment of gastrointestinal malignancy. Clin Colorectal Cancer, 4, 190-5. https://doi.org/10.3816/CCC.2004.n.019
  16. Hanauske AR, Chen V, Paoletti P, et al (2001). Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist, 6, 363-373. https://doi.org/10.1634/theoncologist.6-4-363
  17. Jackman DM (2009). Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg, 21, 154-8. https://doi.org/10.1053/j.semtcvs.2009.06.010
  18. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90 https://doi.org/10.3322/caac.20107
  19. Kohne CH, Van Cutsem E, Wils J, et al (2005). Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol, 23, 4856-65. https://doi.org/10.1200/JCO.2005.05.546
  20. John W, Picus J, Blanke CD et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 88, 1807-13. https://doi.org/10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
  21. Jones RJ, Twelves CJ (2002). Pemetrexed:a multitargeted antifolate (ALIMTA, LY-231514)[J]. Expert Rev Anticancer Ther, 2, 13-22. https://doi.org/10.1586/14737140.2.1.13
  22. Louvet C, de Gramont A (2004). Pemetrexed in advanced colorectal cancer. Oncology (Williston Park), 18, 56-62.
  23. Lu YY, Huang XE, et al (2014), Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac J Cancer Prev, 15, 3335-41. https://doi.org/10.7314/APJCP.2014.15.7.3335
  24. Mabro M, Louvet C, Andre T, et al (2003). Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol, 26, 254-8.
  25. Manegold C, Schmid-Bindert G, Pilz LR (2009). Pemetrexed for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther, 9, 1195-209. https://doi.org/10.1586/era.09.97
  26. Mabro M, Artru P, Andre T, et al (2006). A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer, 8, 1287-92.
  27. Goldberg RM, Sargent DJ, Morton RF, et al (2004). A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 1, 23-30.
  28. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  29. Saltz LB, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 28, 905-14.
  30. Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin pluspemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51 https://doi.org/10.1200/JCO.2007.15.0375
  31. John W, Picus J, Blanke CD, et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 88, 1807-13. https://doi.org/10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
  32. Wei GL, Huang XE, Huo JG, Wang XN, Tang JH (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. https://doi.org/10.7314/APJCP.2013.14.5.2703
  33. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
  34. Xiao Y, Liu J, Liu YC, Huang XE, et al (2014). Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy. Asian Pac J Cancer Prev, 15, 3951-4. https://doi.org/10.7314/APJCP.2014.15.9.3951
  35. Xu C, Huang XE, et al (2014). Drainage alone or combined with anti-tumor therapy for treatment of obstructive jaundice caused by recurrence and metastasis after primary tumor resection. Asian Pac J Cancer Prev, 15, 2681-4. https://doi.org/10.7314/APJCP.2014.15.6.2681
  36. Yang L, Huang XE, et al (2013). Role of MYH polymorphisms in sporadic colorectal cancer in China: a case-control, population-based study. Asian Pac J Cancer Prev, 14, 6403-9. https://doi.org/10.7314/APJCP.2013.14.11.6403
  37. Yang L, Huang XE, et al (2013). Acidic pelvic drainage as a predictive factor for anastomotic leakage after surgery for patients with rectal cancer. Asian Pac J Cancer Prev, 14, 5441-7. https://doi.org/10.7314/APJCP.2013.14.9.5441

Cited by

  1. Effects of Analgecine on Oxaliplatin-Induced Neurotoxicity in Patients with Gastrointestinal Cancer vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4465
  2. Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.647
  3. Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1073
  4. Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3395
  5. Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3425
  6. Pemetrexed in Treating Patients with Metastatic Bladder Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3839
  7. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  8. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485